PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E of 0.03 while AVXL has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
14.82
Net debt of 14.82 while AVXL shows zero net debt. Bruce Berkowitz would look for higher returns justifying the leverage.
No Data
No Data available this quarter, please select a different quarter.
18.83
Similar current ratio to AVXL's 19.86. Guy Spier would investigate if industry liquidity norms make sense for both companies.
No Data
No Data available this quarter, please select a different quarter.